Compound library / Diabetes
Long-acting basal insulin analog providing roughly 24-hour background insulin coverage for type 1 or type 2 diabetes.
| Category | Diabetes |
|---|---|
| Regulatory standing | No approved product cited |
| Typical route | Subcutaneous |
| Half-life | ~12-24 hours (flat, long-acting profile) |
| Common dose range | Individualized starting dose (often ~10 units/day or weight-based), titrated by a physician based on blood glucose |
| Typical cycle length | Ongoing, long-term |
BioHack Track models Insulin Glargine (Lantus/Basaglar) at a half-life of 18 hours, so every dose you log is decayed against that curve and the app shows estimated active levels — not just what you typed.
No FDA-approved product for this compound is cited on this page, and no approved human dose is quoted. Treat the range below as research and community practice rather than a prescribed dose.
Pre-filled pen or vial; no reconstitution needed, but never dilute or mix with other insulins unless specifically directed.
Refrigerate unopened pens/vials; in-use pens are typically good at room temperature for ~28 days — check label.
Prescription medication. Risk of hypoglycemia, especially if doses, meals, or activity change; injection site rotation matters for consistent absorption.
Track Insulin Glargine (Lantus/Basaglar) in BioHack Track. Half-life, dose range and route come pre-filled from this library — log a dose and the app counts your vial down, models what is in your system, and puts it on the same chart as your labs and body composition.
These open a search of each database for Insulin Glargine (Lantus/Basaglar) — they are not citations, and nothing here is evidence for any particular dose. The same links are in the app.
The half-life, route and dose range on this page are compiled from published pharmacokinetic literature, manufacturer and product monographs where one exists, and the ranges commonly reported in clinical and research use. They are kept as a range rather than a single figure because that is what the sources actually support — a half-life varies with route, formulation and the person.
These are not citations, and this page is not a review of the evidence. Where a number matters to you, follow the database links above and read the source. We say so plainly rather than dressing a compiled reference up as one.
Nothing on this page has been reviewed by a named clinician. It is a reference for people already tracking a protocol, not a recommendation to start one.
General reference compiled for use inside the app, not medical advice and not a recommendation to take anything. Dose ranges are what is commonly discussed, not a prescription. Talk to a qualified healthcare professional.